AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03838445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Wave Interatrial Shunt
Description: The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
Study NCT01452555 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video or In-Person Presentation
Description: Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
Study NCT01452555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video or In-Person Presentation
Description: Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
Study NCT03146221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: To look for serum microRNA profiles associated with restenosis
Description: To look for serum microRNA profiles associated with restenosis
Study NCT01413542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin (DPP4 inhibitor)
Description: Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
Study NCT01413542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Substance P,
Description: Substance P intra-brachial artery (2,4,8 pmol/min)
Study NCT01413542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bradykinin
Description: bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
Study NCT01919450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Study NCT04335175 — intervention group
Intervention type: OTHER
Intervention: None - observational study
Description: None - observational study
Study NCT03245645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
Study NCT03245645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
Study NCT03245645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
Study NCT00173537 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: for BMPR II study
Study NCT00173537 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: BMPRII
Study NCT02148861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
Study NCT02148861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once-daily subcutaneously (s.c., under the skin) for 35 days
Study NCT02148861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once-daily for 35 days
Study NCT02148861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once-daily for 35 days
Study NCT03504280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study NCT04341649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Head Massage
Description: Duration 10 minutes.
Study NCT04341649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BREO Helmet Massager
Description: Duration 10 minutes.
Study NCT04341649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Laser Therapy (LLT)
Description: Duration 7 minutes.
Study NCT04341649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham LLT
Description: Duration 7 minutes.
Study NCT04341649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS ear stimulation
Description: Duration 7 minutes.
Study NCT04341649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep and Slow breathing
Description: A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
Study NCT04341649 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxed Reading time
Description: Duration 10 minutes.
Study NCT00922987 — intervention group
Intervention type: DRUG
Intervention: Lyrica (pregabalin)
Description: The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
Study NCT03983694 — intervention group
Intervention type: OTHER
Intervention: Erythrocyte transfusion
Description: The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
Study NCT02397005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-2102
Description: A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
Study NCT02397005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ZL-2102
Study NCT04238832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salt Base Nicotine
Description: Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
Study NCT04238832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Base Nicotine
Description: Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
Study NCT01762826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Myo-inositol
Description: Dietary control plus Myo-inositol
Study NCT01762826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: D-chiro-inositol
Description: Dietary control plus D-Chiro-Inositol supplementation
Study NCT01762826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: D-Chiro / Myo-inositol
Description: Dietary control Supplementation with myo and d-chiro inositol
Study NCT01762826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo
Description: Dietary control plus folic acid 400 mcg daily
Study NCT00345059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Study NCT00345059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00345059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study NCT00345059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT00345059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT01741779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
Study NCT01741779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Description: The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
Study NCT01741779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training & diet
Description: Combination of whole body vibration training and hypocaloric diet
Study NCT00569790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Irinotecan, Bevacizumab
Description: S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA >1.25 to \<1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15.
Study NCT02865395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belladonna and Opium Suppository
Study NCT02865395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belladonna and Opium Suppository
Study NCT02865395 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rectal Exam
Study NCT03885882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 SR1
Description: E0302 SR1, oral tablet.
Study NCT03885882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 SR3
Description: E0302 SR3, oral tablet.
Study NCT03885882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 SR2
Description: E0302 SR2, oral tablet.
Study NCT03885882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 IR
Description: E0302 IR, oral tablet.
Study NCT03440541 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: REGE pro
Description: REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
Study NCT04146363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection
Study NCT04146363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT04146363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT01953822 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
Study NCT06227624 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral zinc sulfate and standard phototherapy
Description: study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
Study NCT00692146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: Oral solution fixed dose (95 mg given orally on two occasions)
Study NCT00692146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution fixed dose (95 mg given orally on two occasions)
Study NCT05369468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine as adjuvant with bupivacaine
Description: to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
Study NCT05369468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain only
Description: to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
Study NCT01947231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
Study NCT01947231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard manual physical therapy
Description: Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
Study NCT01565265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pergoveris in long protocol with GnRH agonist
Description: Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
Study NCT01565265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris in GnRH antagonist protocol
Description: Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
Study NCT02349620 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
Study NCT00653991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLVE-IT
Description: SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
Study NCT00653991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOLVE-IT
Description: SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
Study NCT02192008 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella Typhi
Study NCT02192008 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella Paratyphi
Study NCT03102593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
Study NCT03102593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
Study NCT00537108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting and care management
Description: Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support \& skills-building for school continuation, higher education, and job readiness.
Study NCT02516423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib
Description: oral
Study NCT02516423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: oral
Study NCT02516423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: oral
Study NCT02516423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: IV
Study NCT02516423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: IV
Study NCT03946254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of strength training on executive functions in elderly people with mild cognitive impairment.
Description: Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
Study NCT02314572 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses
Description: Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
Study NCT01919450 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Rubidium-82
Description: Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Study NCT01000480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
Study NCT01000480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
Study NCT03643796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
Study NCT03643796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
Study NCT03643796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.